Chemogenetics Platform for Psychiatry R&D

Inquiry

Chemogenetics, particularly the DREADD (Designer Receptors Exclusively Activated by Designer Drugs) system, enables reversible, cell-type-specific, and remote control of neuronal activity. At Ace Therapeutics, we provide an integrated chemogenetics platform tailored for psychiatric research. It supports target validation, neural circuit dissection, and efficacy evaluation of novel therapeutics in models of depression, anxiety, schizophrenia, and addiction.

How Chemogenetics Works?

Chemogenetics utilizes engineered G protein-coupled receptors (DREADDs) that are no longer responsive to endogenous ligands but are selectively activated by otherwise inert synthetic compounds (e.g., CNO, DCZ, Clozapine). Expression of these receptors is targeted to specific neuronal populations using viral vectors (AAV, lentivirus, HSV) or transgenic mouse lines. Upon systemic or local administration of the designer drug, neuronal activity is either increased (via Gq-DREADD or Gs-DREADD) or suppressed (via Gi-DREADD or KORD), enabling reversible, non-invasive, and sustained modulation of neural circuits.

Fig. 1 Principles of precision neuromodulation through chemogenetics. (Song, Jingwei, et al., 2022)

Core Technical Service Capabilities of Our Chemogenetics Platform

Services	Specific Offerings
Chemogenetic Viral Vector Construction	AAV, lentiviral, and HSV vectors carrying hM3Dq (activation), hM4Di (inhibition), KORD, or rM3Ds. Optional cell-type-specific promoters (CaMKIIα, hSyn, GFAP, GAD, TH) and Cre/LoxP-dependent DIO or FLEX constructs.
Chemogenetic Animal Model Generation	Stereotaxic viral vector delivery for region-specific DREADD expression and generation of transgenic DREADD mouse lines (e.g., R26-LSL-Gq/Gi-DREADD) crossed with Cre-driver lines for cell type-specific neuronal manipulation.
*In Vivo* Pharmacological Manipulation	Systemic (i.p.) or local (intracranial) administration of DREADD ligands (CNO, DCZ, Clozapine). Optimized dosing protocols for acute or chronic experiments.
Behavioral Testing	Light stimulation-independent behavioral assays integrated with chemogenetic manipulation, including tests for anxiety (open field, EPM), depression (TST, FST, sucrose preference), learning & memory (Morris water maze, Y-maze, contextual fear conditioning), social behavior (three-chamber test), and drug addiction (CPP, self-administration).
Validation & Analytics	Immunohistochemistry (IHC) to confirm DREADD expression; patch-clamp or in vivo multi-channel electrophysiology to verify functional modulation of neuronal firing; fiber photometry for simultaneous neural activity recording; histopathological evaluation.
Data Reporting	Full documentation including viral titer certificates, histological images, raw behavioral data with statistical analysis, and circuit mapping results.

Why Choose Our Chemogenetics Platform?

Psychiatric Disease Focus

We specialize in clinically relevant models of depression, anxiety, schizophrenia, PTSD, and addiction. Our team of experts has deep expertise in the field of psychiatric disorders.

Flexible Tool Selection

We support multiple DREADD variants (hM3Dq, hM4Di, KORD, rM3Ds), ligand options (CNO, DCZ, Clozapine), and delivery routes.

Integrated Services Workflow

We provide end-to-end chemogenetics services, from construct design and stereotaxic surgery to behavioral assessment and functional validation.

Ace Therapeutics offers customized chemogenetics solutions to support neural circuit research, target validation, and preclinical efficacy studies in psychiatric disorders. Contact our experts to discuss your project and discover how our integrated platform can help accelerate your research.

References

Gao, Jingyao, et al. Advances in chemogenetics: a review of DREADDs and its application in psychiatric disorders. Molecular Psychiatry. 31.1 (2026): 480-497.
Song, Jingwei, et al. Chemogenetics as a neuromodulatory approach to treating neuropsychiatric diseases and disorders. Molecular Therapy. 30.3 (2022): 990-1005.
Li, Shaowei, et al. Optogenetics and chemogenetics: key tools for modulating neural circuits in rodent models of depression. Frontiers in Neural Circuits. 19 (2025): 1516839.

Inquiry

First Name *

Last Name *

Business Email *

Phone

Company/Institution

Job Title

Services or Products of Interest *

When do you expect your project to start?

Project Description

* Please note that all of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

* Tick to confirm the Research Use Only (RUO) statement.